Verici Dx Share Chat (VRCI)

WRAP under subscribed tells you everything you need to know

Barrington and Paul Hill have failed to scam the market this time

They clearly couldn't publish accounts without the raise, as going concern assumption would be qualified in the audit report. That does mean, however, that there will be enough cash from 12 months of signing date of the accounts post-raise

Especially when the CEO said the accounts would be published in May.

Something has gone wrong between that claim that they would publish the accounts in May and now having to raise in June, still without accounts.

Auditors would have required visibility on ability for it to continue going concern over next 12 months before signing it off - but management should have known this. Did trading deteriorate over the last few weeks, or were they simply not paying attention to the numbers?

Worst part for anyone that was brave enough to hold to this point is they say this raise will fund them to 'at least' end of 2026. Not even a full year. Unless they suddenly turn things around, begging bowl comes out again early 2027.

Something very amiss here.

To launch a placing without the release of the 2025 accounts - shocking. SB

They have just announced their funding which is neither fish nor fowl. A right b*ggers muddle.

Potentially, though I see this going the same way as destiny pharma. Lunglife AI and Polarean

For transparency I’m down 36k in this and topped up every time barrington lied to the market

Lost 60k in polarean and 12 in lunglife

Once bitten twice shy I’ll be avoiding speculative garbage from now on

Nova . The answer is Hill gets a fee . The more he pushes it the more fees he gets. It still has good potential. It’s been very poorly directed and managed despite some unfortunate timing issues and The Kennedy / Trump factor. Still feel Vrci is the best potential out of the Bains stable, mainly because it should become mandatory for kidney transplants, save money, outcomes and lives .

Company appears to be burning cash at c.£500k a month. On that basis company was going to run out of cash this month - raise was therefore imperative to survive. They now have enough funding to get through to end of year based on latest 2026 revenue target - $5.1m - no clarity on whether this is all Tutivia or PRTA income. Then its back for more cash again in 6 months. Current growth forecasts are nowhere near strong enough. No accounts yet. More dilution on way - share price likely to slip below placing with next raise at 0.2p. Best outcome here is a takeover imo. SB

There’s the raise

Probably worth taking part if you can and flipping your shares onto the next poor b*stard

Paul Hill should be ashamed of how he collaborates with companies like this to raise capital. He’s not your friend

Paul Hill will be congratulating the Barrington again next week on her fith or sixth trip ‘off to the races,’ to see how quickly she can race through the new £2.5 million raise. They had 1.3 million dollars net cash end of March. Singers the brokers managing the raise, were the ones saying Vrci is worth 2.9p a share, so not that confident with the raise @ .35p (nearly 10 times lower). Is this all they think they need or all they could raise? I suppose it just slipped her pretty little mind that she had run out of cash again after promising ‘at latest, year end results end of may.’ We simply have no idea how quickly income could accelerate here. And by the look of things Barrington as clueless as ever. In the lap of the gods.

What's another 2.7m? I have subscribed for the minimum. Rather under water here. Upside is not fantastic. Chance of success and company making it to profitability is not that high. However, my £100 pales in comparison to those who have just put in 2.5m - they must have belief.

Hawker, "They all get a big fat ‘F’ for their work here" They should be sacked. I remember when RENX issued the RNS about Tempus and the SP rocketed only the be reversed by Polar dumping all their shares that afternoon when the SP was still on a roll. NXCI called it right with the" Myopic" description of the City boys.

@Mikemine - 100% agree with your comments. The fund managers and the house broker had the opportunity to create a positive feedback loop here, and instead they chose to create the opposite. They all get a big fat ‘F’ for their work here, shockingly poor quality investment management. No wonder their fund flows continue to vote with their feet.

Such a shame as the company are doing an increasingly material job of growing sales and executing on their objectives and milestones.

Thermo Fisher should soon be pushing PTRA, too.

Investors and brokers should be hanging their heads in shame on this round. Should have come at a significant premium to the last round, not to mention to the unsupported illiquid price on AIM.

SC, you must know about the fools in the City. No way would VRCI have gone in offering a discount. They would have asked for a premium such was the quality of their story. It would be the self congratulatory idiots in the fund manager's office that can now boast that they have screwed down another company, but stand back a bit and see what they have done. Sentiment is all and they have destroyed it here and for what, a piddling little percentage. I expect these guys already hold shares here so it would have been in their interest to pay a small premium which would turn the sentiment positive and also increase the value of their holdings. It'll be difficult for VRCI to improve sentiment and that is the last thing the SP needs. It's no wonder there has been an exodus of companies leaving the London markets.

There's your placing.

Look at the discount. Exactly the risk I pointed out just 3 days ago with this CEO's form for discounting. Perhaps instead of arguing with me, you should have been paying more attention.

Let's see how the happy clappers spin this one.

When you fundraiser, especially if you are in a weak position like broke and early stage, the strike price is mostly dictated by the guys giving you the money. Ask for a premium and they will laugh at you. When you give a podcast it's obvious that you are going to ramp up the company's prospects. That's what a CEO does. Does anybody expect anything different? NXCI has nailed it in that this sector is hampered by the myopic City and that's one of the reason many companies have left for America etc. In fact NXCI, goodness knows who the guy is, has a good handle on this sector and should be taken seriously.

Saw you coming last year!

This time next year, you will be joined by Genincode!

Barrington has been a disaster. She has comprehensively shafted her shareholders while banking a huge salary. She seem stotally oblivious to the damage.

Imposing one's own deadlines for publishing audited accounts and missing them is neither good corporate governance or the way to manage shareholder trust/expectations. SB

Let’s hope so

Results way ahead of expectations hence delay .Linkendin nearly 1400 up 10%last month all nephgrologists.

Looks good.

Thanks SB

SB. Last year Full Results were published June 30th with accelerated book build raise June 11th. Sounds pretty good to me if and when they can get on top of finances.

The organisers of Mello 2026 previously announced on 15th May that Verici (Sara Barrington - CEO) would be exhibiting and presenting on 2nd June. The latest schedule shows neither is now happening. This may or may not be linked to the late publication of the audited accounts. Cause for concern? SB

Subject: Re: May Audit Expectations – What to look out for

​Good question on the upcoming May audit. Based on the current trajectory and what needs validating, here is a breakdown of what the statement is likely to focus on and confirm:

​Verified Financials & Liquidity: Expect absolute confirmation of the cash sitting in the accounts as of the period end, alongside a clear reconciliation of payables, receivables, and money yet to be collected.

​Sales Performance & Velocity: While the audit looks at the trailing data, the focus will inevitably shift to how past sales bridge into our current momentum. The Q1 trading update already proved an explosion in sales velocity, with Tutivia : volumes up 32% quarter-on-quarter.

​Enhanced Cash Runway: The cash runway is fundamentally enhanced by this commercial traction. With a cleaner cash collection cycle via Medicare/Medicaid and a reported $1.6m in receivables, the commercial engine is starting to outpace the historic cash burn.

​Objective View of the Business Model: Ultimately, this audit should provide a grounded, objective look at the broader business model. The 32% growth shows the platform is scaling rapidly, proving the commercial model is highly successful.

​Looking forward to the RNS. It should provide a very solid foundation ahead of the AGM next month.

All the best for all shareholders and beware of tree shakes [ there be plenty of those and stop worrying about placements]

Karlvonwise

Personally I'm looking for confirmation that previously announced $3.8m revenue has been fully accepted; current cash position; an indication of monthly cash burn; when further payments from Thermo are anticipated (Lack of commercial progress in PRTA is one of the reasons company is in the precarious position it is); a clear indication expenses are under control bearing in mind cash position; Q2 trading; and - this is very important - a route to breakeven. Without that the market cap will continue to get battered and the risk of at least one highly dilutive funding round remains. SB

The audit section of the accounts likely to be bland.

It's the going concern section to pay attention to. cntrl+f "material uncertainty"

What might that say,any ideas anyone,

0.425 to buy,same as yesterday bit with free news,now im thinking of buying,but can understand we could be diluted soon what a dilemma i have

Here it goes 0.47.5 to buy and this will fly !

All the best to all share holders

Karlvonwise

No point in buying anything at the minute when SB is planning more dilution

The last placing was done at a c.40% discount to the previous day share price - so 0.25p placing price would be in the ball park. Trouble is to raise what they need to survive next 12 months is going to see a massive dilution - probably somewhere between 1b and 2b new shares. 3b ordinary shares at 0.25p isn’t far off current market cap so the math adds up. Tough times ahead methinks. SB

£20k+ available at that price (5m shares) if anyone's feeling brave.

Just had a quote to buy £100 and it showed 0.415p

This practice is not restricted to VRCI as far as I can see.

Had a communication from the Stock Exchange saying they do not attach Buy/Sell labels when they report trades so basically LSE are guessing when they attach a label. I bet most investors don't know this and take the information as Gospel. It is giving a negative bias to the data as it's not a question of swings and roundabouts.

Very active on the shares , but still buys being listed as sells.

Everything above 0.43 is a buy

Best wishes

Karlvonwise

Hi Silverblade, appreciate the detailed breakdown. It’s always good to have a realist perspective to balance out the noise.

​I suspect you might be framing this from a 'worst-case' logistics view, which is fair for AIM, but there are a few variables that might steer us toward a smoother H2:

​The Revenue Engine: While the H1 loss projection makes sense on paper, the 32% volume growth reported in the trading update suggests the commercial engine is accelerating rather than idling. If that momentum carries into Q2, the 'bleed' might be significantly lower than a flat extrapolation suggests.

​The Receivables Buffer: That $1.6m in receivables is a significant non-dilutive reserve. Combined with the potential $1m Thermo milestone you mentioned, it provides a decent defensive line that could push the 'need' for capital much further back than Q3.

​The Whale Factor: The movement of 118 million shares (7.8%) into strong hands via UBS is hard to ignore. It feels like institutional positioning in anticipation of the commercial 're-rating' once the Audit confirms the runway.

​I’m personally holding firm until the May 31st Audit drops. If the numbers are 'Sterling,' we might find the company has a lot more fuel in the tank than the market currently credits them for.

​Good to have the debate—best of luck!

Karlvonwise

Growth is a obviously a good sign Karlvonwise - and as you note the new director of sales would seem a solid appointment. I think the $0.8m thermo payment you refer to was in 2025 numbers - so its taken into account in the $3.3m cash at the start of the year. Company is likely to report a 2025 ebitda loss of c.$5m in a couple of weeks - and based on current revenue (c.$1m Q1 2026 - hopefully some growth into Q2) - it will be in a similar position H1 2026 ie a H1 2026 ebitda loss of $2.5m. There is a further milestone due from Thermo (from memory it is in the region of $1m) which would be very helpful - and as you note there is the $1.6m receivables noted in the trading update. New capital will be required in Q3 2026 imo - and based on previous fund raising you would think they will look to a 12 month cash runway - $6m? That level of support from II's would provide a clear signal that there is real belief on the commercial viability of the business. The downside is the likely doubling of shares in circulation - but needs must. SB

Fair points, Silverblade. It’s definitely been a long road for us holders. However, I’m leaning slightly more optimistic on the cash front. With the $1.6m in receivables and the recent $0.8m milestone from Thermo Fisher, the H2 2026 runway feels a bit more secure than usual for an AIM junior.

​Also, that 32% volume growth in Q1 is hard to ignore—especially with someone of Keith Gilliard's caliber now steering the ship. If the Audit confirms these trends by the end of May, the market might finally have to look past the 'placing' fears. GLA!

All the best Karlvonwise

I'm in RENX as well Mikemine so well aware of how UBS are handing these particular investments - and as you say it's probably best to ignore despite the numerous RNS announcements they make.

I'm pretty sure the majority of posters here are looking for VRCI to succeed. Its been a painful investment journey for all here to date - but recent progress is positive. There is no doubt they will require to raise money this year - breakeven is c.$10m pa so there is still a sizeable monthly cash burn. Current cash runs into H2 2026. AIM listings are historically for company's in the early phases of development who need access to capital - nothing new there - for VRCI that capital will be used for both general corporate expenses and more specifically the sales team. Perhaps they will wait until H1 2026 is complete to show the market what has been achieved - although progress is required with Thermo relationship rather than 100% reliance on Tutivia revenue. In the meantime the market continues to place a disappointingly bleak valuation on the business - and is likely to continue to do so until placings, ongoing losses are out the way. SB

Just had a quote to buy of 0.4538p and a quote to sell of 0.4503p A pretty tight spread and way different to what is being quoted by LSE.

I've surprisingly had a very quick response from LSE and I'll post it below.

"Thank you for your email. As we're not told by the Stock Exchange what is a buy or sell, we're forced to use an algorithm to work it out.

We calculate the trade type based on the trade price being higher or lower than the mid price at the time of the transaction. Sometimes this calculation does not work, or the price is the opposite side of the mid price. This means we are either unable to calculate what type of trade this is at all, or the calculation shows it as the wrong type of trade (a buy instead of a sell for example).

Unfortunately, it's a long standing issue as the Stock Exchange doesn't provide the correct information for trades, so any website like ours has to use an algorithm to determine what type of trade we're being sent. "

So, basically they know there is a problem but can't or won't do anything about it. A prominent disclaimer might help or stop classifying trades as buys or sells at all. Better still would be the correct information being transferred from the stock exchange.

I'll probably have to go to whoever runs AIM over this. It's giving AIM a bad name for being negative. If anybody else investing elsewhere has the same experience can they let me know.

At time of writing there was 2 trades. One was. A sell for 75000 shares @ 0.454. And the other was fa buy for a small amount of shares @ 0.50 .

The reason I know the 75000 shares was a buy is because it belongs to me :)

Best wishes all Karlvonwise

@mikemine as long as it makes you feel better , then thats quality 😀

Best wishes Karlvonwise

You are probably right K but I just had to do it.

@Mikemine I genuinely think your time may be better spent making a cup of tea than writing to LSE about “misrepresentation.”

At least the tea has a guaranteed return and probably tastes better too 🙂

Best wishes,

Karlvonwise

@mikemine I think they’ve probably assembled the team they need now.

The commercial side has already done an excellent job, and with Keith Gilliard now onboard, they have someone with direct industry experience who likely understands how to get past the gatekeepers and reach the real decision-makers within transplant centres.

As for another fundraise, that remains a possibility rather than a certainty. A lot will depend on how quickly adoption and revenues continue to grow over the next few quarters.

If people are interested, I can also look into some of the other recruits and post a breakdown of their backgrounds, experience, and areas of expertise.

I’ve already done some research on two of them so far.

I've written to LSE pointing out the large scale misrepresentation of trading data and asking them to rectify it. It must be a computer glitch but it must affect sentiment about the underlying share/company including VRCI. It's hard enough making money on AIM without this negative bias being built in.

It's not just here K. I made 2 largish buys of RNLX a few days ago and they were both classed as sells. There were a few other trades at almost the same price so I took them to be buys as well. If this is widespread over AIM it's no wonder it's got a bad reputation for being negative. It's not a small thing as it can, and probably does, influence sentiment about stocks.

I’ve spent the day analyzing the trade logs, and there’s a clear divergence between the ‘reported’ sentiment and the volume reality.

​I’ve made two buys yesterday (including a final 22k at 0.455p right before the close). Interestingly, both were marked as ‘Sell*’ on the LSE tape despite being confirmed buys. This suggests that much of the 2 million+ volume we’ve seen today is actually mid-price accumulation being misidentified by the algorithm.

​The logic is simple: if that 2 million volume consisted of genuine sells, we would be looking at a collapsing share price. Instead, we’re seeing a solid floor being built at 0.45p.

​With the Full Year Audit due by the end of this month, it looks like someone is ‘hoovering’ up every available share without moving the price—yet. They’ve recognized that the 32% growth and the Keith Gilliard recruitment have fundamentally changed the risk/reward here.

​Positioned at x amount of shares and happy to wait for the official numbers to drop.

Snagged a final 22k at 0.455p at 16:28. Naturally took that price without hesitation. If you track the trades today, the pressure is clearly on the buy side, although mafked as sells . Great to see the conviction building as we head into a big month for the company

I've just done a dummy buy and the quote to buy was 0.454p

I think you've summed up the position very well. The only thing to add is the tests are trying to progress in an established market rather than trying to carve out a demand. The clinicians want Tutivia and Clavara so watch this space.

I’ll leave the 'AI' paranoia to a certain fabourite friend of mine—I’ll stick to the RNS filings and the clinical data.Since he finished casting doubt on my previous plays, let's address the only real, documented risk at Verici:

The Cash Runway.As of the last update, Verici’s runway extends into H2 2026 (supported by the £6.35m raise). We are in a race against time to hit cash-flow positivity. But look at the fuel we just added to the engine: The 32% Velocity: 392 tests in Q1 isn't just a number; it’s proof of a 32% quarter-on-quarter growth trajectory. At $2,650 (£2,100) per test via Medicare, the gap between 'burn' and 'earn' is closing rapidly.

You don't hire a Senior Director from the industry leader (CareDx) unless you are moving for the kill. In medical sales, it’s about who you know. Gilliard has the Rolodex to bypass the typical 18-month 'evaluation' phase at US centers and move straight to protocol adoption.While we focus on the runway, CareDx and Natera are circling each other in a $96m legal battle (probably appeals to come). Their cfDNA tests are reactive—they detect cell death (damage control). Verici’s RNA-based tests (Clarava and Tutivia) are proactive, catching the immune response before the damage is done. Yes, there is a risk of a loan or small dilution in H2 to bridge the gap. But I’d rather back a company diluting for Commercial Expansion with a CareDx heavy-hitter at the helm than a 'zombie' company with no sales.If the competitors want to 'circle' for our assets, they’ll find the price going up every time Gilliard adds another transplant center to our 20% US coverage. I'm happy with my position at 0.459p. See you at the May Audit x

For my critical friend @ Stockscapital : since you like to dispel my experience in AFC and Mast (QDE), then allow me to share my research in VRCI and its competitors for you to cast doubt on it:

While you’re stuck on the QDE ‘back story,’ I’m looking at the Future of Transplantation.

Verici’s main competitors, CareDx and Natera, have spent years in a ‘war of attrition’ in the courts, with CareDx recently hit by a $96 million jury award for false advertising. They are distracted by litigation and ‘damage control’ for their own products.

The science also favors Verici. The rivals’ tests (cfDNA) are reactive—they wait for the organ to start dying before they trigger an alert. Verici is the only player covering the full patient journey:

Clarava (Pre-Op): Identifies risk before the first incision. No one else has this.

Tutivia (Post-Op): Uses RNA expression to catch the immune response before the organ takes damage.

This is why the recruitment of Keith Gilliard (who came directly from CareDx) is the pivot point. He didn’t jump ship from an industry leader to join a ‘pump’—he joined because he knows the competitors are tied up in legal drama and Verici has the ‘proactive’ product that surgeons actually want.

I’ll stick with my buy this morning at 0.459p, as well as my previous buys and the man with the Rolodex. I’m happy to let you keep casting doubt while the 32% growth turns into a market breakout.

@Stockscapital : I would be suspicious of that AI generated post. These boards have unfortunately become full of them.

Bit of clanger in that particular ChatGPT copy and paste to refer to QDE to try and pump this. Look at that company's back story, the long term chart, and fact it is now suspended

It’s easy to cry ‘AI’ when you don’t have an answer for the actual facts.

Let’s look at the ‘back story’ you mentioned: Quantum Data Energy (QDE) requested a temporary suspension on May 1st for a very specific, documented reason—their auditor, Crowe UK LLP, resigned unexpectedly on April 29th (RNS 2880C). Under FCA rules, you cannot trade if you miss the audit deadline. That is a regulatory hurdle, not a failure of the business model or their fund-raising.

In fact, if you’d read the news from April 23rd and 29th, you’d see they actually confirmed an amendment to their equity raise and commenced construction on the Bordesley 5 MW project. They are raising money and building assets while dealing with a technical audit delay.

I’m not ‘pumping’ anything—I’m identifying a pattern. Like AFC Energy at Dunsfold, companies often face ‘turbulence’ before the personnel they recruit (like Keith Gilliard here at Verici) propel them to the next level.

I’d be more suspicious of posters who ignore RNS filings to push a negative narrative than those who actually do the research. I’ll stick with the 32% growth and the ex-CareDx leadership. Good luck with the guesswork.

I will now refer to my next post, to help you out as you seem to like to live in the past

I would be suspicious of that AI generated post. These boards have unfortunately become full of them.

Bit of clanger in that particular ChatGPT copy and paste to refer to QDE to try and pump this. Look at that company's back story, the long term chart, and fact it is now suspended.

@Mikemine — My own thoughts on the current action:

I’m starting to believe that when you see this level of strategic "static" (the 1-share trades and mid-price walking), it’s a clear sign of an investor trying to suppress the SP to manufacture a better entry or average down before the next leg up.

The real "North Star" here isn't the daily noise—it's the TR-1 trail from UBS. Having a Tier-1 global powerhouse constantly active on the register provides a level of institutional validation you just don't see on most AIM stocks of this size.

With the 32% volume growth confirmed in Q1 and the results looming, I’m looking past the manipulation. If the "Goliaths" are playing games to get cheaper shares, I’m happy to follow their lead and build my position while they’re still keeping the lid on it. Fundamentals always win out in the end.

.

If Karlvonwise is correct it looks like someone is trading lots of 1 share sells, presumably to lower the SP. It's been going on for 3 sessions so far.

Aye ah just love pessimism gies me rah chance fur mehr cheap shares .If ye boys cannie see the value here jist sell and dae wan an leave it fur the laddies wae rah baws ah steel.

Karlonwise - I appreciate investors have the right to buy/sell for whatever reason - the trouble is these larger trades are dragging the share price lower and lower which will ultimately lead to an increasingly significant number of new shares being issued as part of the fundraise which we all know is coming. I had hoped there may have been a bit more positivity after the Q1 sales and any new money would be raised as a minimum at 0.5p, which is looking petty optimistic. SB

Does that mean someone is trying to lower the price?

This month is going to be one for this stock

A few of those sells are buys including mine or not a large amount of shares .

All the best Karlvonwise

Take no notice of the RNSs concerning UBS. Over on RENX they were announcing large percentage holdings and then saying they went down to zero in a matter of days, just like they've done here. This backwards and forwards went on for weeks. It bore no relationship to trades and nobody could understand what UBS was doing. Looks like it's started here so best to ignore it.

Spot on Mikemine: It's frustrating to see high-conviction buys show up as sells just because of where they sit in the spread. The automated reporting is definitely flawed. Either way, the volume is there, and with UBS on the register, the 'direction of travel' seems clear regardless of how the MMs label it!

Not uncommon Karlvonwise. I bought in 2 trances in another company and they both showed as sells. It happens all the time. I was wondering if the categorisation of sell/buy is adjusted according to what way the MMs want the SP to go and justify their pricing.

Donmac101 38 Yrs

Time in the market doesnt mean you (or i) are doing it right

What i am saying is that it is blatantly obvious that Barrington has started to engage Paul Hill et-al because she needs funding, which means dilution

Not saying this isnt a good company (it is, and i hold considerable holdings in a SIPP)

What i am saying is that now would be a foolish time to buy shares if you think there is a risk of dilution (which i do)

Wait until they give away more equity and then buy

Plonkerito only 50 years in the market and YOU?

Spoken like somebody that doesn’t understand how the stock market works

It’s irrelevant, really, whether or not tests ramp up and revenue grows, if the board simply use it to further dilute share holders

You can buy a rubbish business at the right time and make money

You can also buy an amazing company at a rubbish time and lose money.

Any investor with an ounce of sense wouldn’t be buying shares in this until the fundraise is out of the way. You’re literally asking to lose money

Get Paul Hill to go TR1 if he’s so convinced.

Verici will be the biggest gainer on AIM this year regardless of fundraise as testing ramps up .It is now a company with real life saving tests that America needs.Disregard the doomsters UK is full of them the end is nye ect.

Big Pharma will kill for verici assay urine samples ect over many years

Not much to add to that SB. AIM is a brutal market for investors and companies alike. I can't see them not getting the next fundraising away as the upward accelerating revenue is there for all to see. I look forward to the next update at the end of May and will be very interested to see how TF is doing with Clavara. They've had it for nearly a year now and should be fairly near bringing it to market, at least I hope so. If TF put their sales force behind it the potential for a quick revenue lift is very good IMHO. Would be nice to get a detailed update on that one rather than a brief mention. Meanwhile Tutivia is ramping up beyond expectations and, with a $400 mn market out there, it looks very positive. Dilution is a given I reckon but it should unlock greater penetration and lovely profits. Just got to wait and see.

Don't take any of this as advice. It's just my ramping thoughts on the reasons I'm here.

Mikemine - I've been an investor here for some time and went through a heavy anti barrington phase at the point of the 0.5p fundraise last year for the reasons you note. I agree with a lot of your recent observations. Recent posts here by others are still venting - and to some extent that is understandable given the low market cap/share price. Whether that is from a position of having a holding here or just throwing muck is up to those individuals. All boards have this from time to time. Goes with the territory. It has been known for some time there would be at least one, possibly more funding rounds required. Participate and retain current % shareholding; or don't and get diluted. Positive sales progress has certainly not been replicated at valuation levels. If you believe that VRCI has a viable, commercial future, then even with additional shares coming into the market it looks a decent bet. They may look to raise a similar amount as last year - which should see them well into 2027 - and possibly nearing breakeven. Its the old 'short term pain for longer term gain' mantra. SB

I honestly don't know why you guys are here if you have so little regard for the CEO. There are hundreds of companies out there. I'm sure you can find one or two that has a CEO you can find satisfactory. If you are sore that you have lost money here, join hundreds of PIs out there, including me, and move on to save your sanity.

The market markers are keeping this stock low for some reason

I'm been asking for quotes to buy today and I was quoted 0.50p to buy. I accepted one of them and sure enough I bought at 0.50p yet it showed up as a sell (red) on here. I guess the other trades at that price are buys as well. Quite misleading.

Barrington was not the CEO of LLAI when they went private. She had held a non-exc post on the Board for some time prior to the move to private. Let's get our facts right shall we.

The real worry with barrington at the helm is that she sees equity holders as merely a tool to reach her goal; to that end, the risk with her is that she wipes out equity or takes the company private (exactly like she did with LLAI)

I wouldn’t be buying until she does

Has anyone ever seen a CEO of any company remain in position after overseeing a near total 99% destruction in the share price?

I’m definitely not willing to take part in the next fundraise

Perhaps barrington should put her money where her mouth is

The reality is that narcissists don’t care about collateral damage. Their primary focus is to secure the business and its intentions (including board salaries)

Equity holders are bottom of the pile, unfortunately

So I would expect we will find about the raise when they release the results

I wonder what the price will be 0.55

An acceptance of the fact a raise is coming!

Only I have been saying it since the last one and have stated on multiple occasions that it will be at 0.25p. Watch this space!

U

Don't take any notice of UBS holdings RNS's. The pattern is turning in to the same we had on Renalytix. They built up a holding and then they were gone in days and then they reported a big holding and then again it went to zero within a few days. Nobody knew what to make of it but the pattern went on for weeks.Best to just ignore.

Is it a good time to buy now,or wait until may results

Could have got whiff of a major sniffing around at bargain prices? Big funds in minnows like UBS tells me somethings afoot.

Hmm,seem to be missing an RNS on this site, issued by the company on 30 March.Opposite of the one released yesterday.